Supplements
March 2024:
Managing IBS-C: Focus on Symptom Control
Patient Case JP is a 24-year-old man referred for a second opinion in Gastroenterology. He reports a yearlong history of lower abdominal pain and discomfort, bloating, […]
January 2024:
Highlights From the 2023 Advances in Inflammatory Bowel Disease Conference
A Review of Selected Presentations on Inflammatory Bowel Disease From the 2023 AIBD Conference December 14-16, 2023 • Orlando, Florida Anti-TNF Therapy for inflammatory bowel disease […]
December 2023:
Ulcerative Colitis
Highlights in Ulcerative Colitis From the American College of Gastroenterology 2023 Annual Scientific Meeting
A Review of Selected Presentations From the ACG 2023 Annual Scientific Meeting • October 20-25, 2023 • Vancouver, Canada Early Symptomatic Improvement With Guselkumab Induction Treatment […]
Crohn’s disease
Highlights in Crohn’s Disease From the American College of Gastroenterology 2023 Annual Scientific Meeting
A Review of Selected Presentations From the ACG 2023 Annual Scientific Meeting • October 20-25, 2023 • Vancouver, Canada Analysis of Upadacitinib in IBD: Evaluating Safety […]
October 2023:
IBS-C
Mechanism of Action Considerations in the Management of IBS-C
Patient Case A 23-year-old biology PhD candidate presents for further evaluation of her gastrointestinal (GI) symptoms (Table 1). These symptoms have been present for the past […]
September 2023:
Irritable Bowel Syndrome
Raising the Bar in the Management of IBS-C
Patient Case A 47-year-old woman presents with complaints of occasional constipation during the past several years (Table 1). She states that she has experienced increasing abdominal […]
July 2023:
Highlights in Ulcerative Colitis From Digestive Disease Week 2023
A Review of Selected Presentations From DDW 2023 • May 6-9, 2023 • Chicago, Illinois Long-Term Safety of 3 Years of Ozanimod in Moderately to Severely […]
April 2023:
Understanding the Current Approaches in the Management of IBS-C: A Case Study
Patient Case A 36-year-old woman presents with persistent abdominal pain and constipation (Table 1). Upon inquiry, she states that she has experienced abdominal and bowel-related symptoms […]
Ulcerative Colitis
Highlights in Ulcerative Colitis From the 18th Congress of ECCO
A Review of Selected Presentations From the ECCO Meeting • March 1-4, 2023 • Copenhagen, Denmark Analyses From the Phase 3 True North Study of Ozanimod […]
December 2022:
Inflammatory bowel disease
Highlights From the 2022 Advances in Inflammatory Bowel Diseases Conference
A Review of Selected Presentations on Ulcerative Colitis From the 2022 AIBD Conference • December 5-7, 2022 • Orlando, Florida Four Studies From the True North […]
November 2022:
Ulcerative Colitis
Highlights in Ulcerative Colitis From the American College of Gastroenterology Annual Scientific Meeting
A Review of Selected Presentations From ACG 2022 October 21-26, 2022 • Charlotte, North Carolina Duration of Response to Ozanimod After Treatment Withdrawal: Results From the […]
July 2022:
Highlights in Ulcerative Colitis From Digestive Disease Week 2022
A Review of Selected Presentations From DDW 2022 • May 21-24, 2022 • San Diego, California Recapture of Response With Ozanimod in Patients With Moderately […]
April 2022:
Ulcerative Colitis
Highlights in Ulcerative Colitis From the 17th Congress of the European Crohn’s and Colitis Organisation
Rapidity of Ozanimod-Induced Symptomatic Response and Remission in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Induction Period of True North Ozanimod is […]
December 2021:
Inflammatory bowel disease
Highlights From the 2021 Advances in Inflammatory Bowel Diseases Conference
A Review of Selected Presentations From the 2021 AIBD Conference December 9-11, 2021 The Past, Present, and Future of Inflammatory Bowel Disease At the 2021 Advances […]
November 2021:
Highlights in Hepatocellular Carcinoma From the 2021 European Society for Medical Oncology Congress
IMbrave150: Exploratory Efficacy and Safety Results in Patients With Hepatocellular Carcinoma Without Macrovascular Invasion or Extrahepatic Spread Treated With Atezolizumab + Bevacizumab or Sorafenib The global, […]
May 2021:
Primary Biliary Cholangitis
The Evolving Use of Biochemical Markers in the Management of Primary Biliary Cholangitis: A Clinical Perspective
Kris V. Kowdley, MD, Gideon M. Hirschfield, MA, MB BChir, FRCP, PhD, and David E. Jones, BM, BCh, FRCP, PhD, OBE
Abstract: Primary biliary cholangitis is a chronic autoimmune liver disease characterized by immune-mediated damage to interlobular bile ducts within the liver that may lead to cholestasis, […]
April 2021:
Ulcerative Colitis
The Guide to Guidelines in Ulcerative Colitis: Interpretation and Appropriate Use in Clinical Practice
William J. Sandborn, MD, FACG, AGAF, Brian G. Feagan, MD, Stephen B. Hanauer, MD, FACG, and Gary R. Lichtenstein, MD, FACG, AGAF, FACP
Introduction In October 2020 and January 2021, a group of clinical experts in the field of inflammatory bowel disease (IBD) convened virtually to discuss current ulcerative […]
February 2021:
liver disease
Highlights in Primary Biliary Cholangitis From the EASL 2020 Digital International Liver Congress, the ACG 2020 Virtual Annual Scientific Meeting, and the AASLD 2020 Liver Meeting Digital Experience
Long-Term Efficacy and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis: A Demographic Subgroup Analysis of 5-Year Results From the POISE Trial […]
January 2021:
IBD
Highlights From the 2020 Virtual Advances in Inflammatory Bowel Diseases Conference
A Review of Selected Presentations From the 2020 Virtual AIBD Conference • December 9-12, 2020 Positioning Biologics and Small Molecules in the Management of Moderate […]
liver disease
Guidance for Coagulation Management in Patients With Acute or Chronic Liver Failure
Robert G. Gish, MD, Fredric G. Regenstein, MD, Steven L. Flamm, MD, R. Todd Stravitz, MD, FACP, FACG, FAASLD, and Joel M. Brothers, MD
Abstract: This monograph delineates clinical guidance for the diagnosis and management of patients with liver disease who have coagulation disorders or who are at risk for […]
October 2020:
gastroenterology
Congenital Sucrase-Isomaltase Deficiency: What, When, and How?
Disaccharidase Deficiency: An Overview for Gastroenterologists Focusing on CSID Overview of Carbohydrate Metabolism Nearly half of the average Western diet is composed of carbohydrates,1 which are […]
September 2020:
Nonalcoholic Steatohepatitis
Highlights in Nonalcoholic Steatohepatitis (NASH) From Digestive Disease Week 2020
A Review of Selected Presentations From DDW 2020 Obeticholic Acid Improves Experimental Non-Invasive Markers of Non-Alcoholic Steatohepatitis and Advanced Fibrosis: Results of a Secondary Analysis […]
Crohn’s disease
Optimizing Strategies to Assess Mucosal Healing in Patients With Crohn’s Disease
Douglas C. Wolf, MD, Eugene Greenberg, MD, FACP, FACG, AGAF, and Miguel D. Regueiro, MD
Abstract: In the past 5 years, the goal for the treatment of Crohn’s disease has evolved from managing patient-reported symptoms to the new paradigm of […]
August 2020:
Ulcerative Colitis
INFORM UC: An Update on Contemporary Management of UC
Maria T. Abreu, MD, Stephen B. Hanauer, MD, FACG, and Gary R. Lichtenstein, MD, FACG, AGAF, FACP
Introduction In July 2020, a group of clinical experts in the field of inflammatory bowel disease (IBD) convened virtually to discuss current issues and advances […]
Nonalcoholic Steatohepatitis
Noninvasive Tests (NITs) in the Management of Nonalcoholic Steatohepatitis (NASH)
Stephen A. Harrison, MD, Quentin M. Anstee, BSc(Hons), MB BS, PhD, MRCP(UK), FRCP, and Rohit Loomba, MD, MHSc
Abstract: Nonalcoholic fatty liver disease (NAFLD) affects approximately a quarter of the adult population in most Western countries, particularly those in Europe and North America. […]
December 2019:
IBD
Highlights From the 2019 Advances in Inflammatory Bowel Diseases Conference
A Review of Selected Presentations From the 2019 AIBD Conference • December 12-14, 2019 • Orlando, Florida A Practical Approach to Anti-Interleukins in IBD 2020 […]
IBD
Highlights in IBD From the American College of Gastroenterology 2019 Annual Scientific Meeting and United European Gastroenterology Week 2019
A Review of Selected Presentations From the ACG 2019 Meeting • October 25-30, 2019 • San Antonio, Texas and UEG Week 2019 • October 19-23, 2019 […]
August 2019:
IBD
Highlights in the Management of Ulcerative Colitis and Crohn’s Disease From the 2019 Digestive Disease Week Meeting
A Review of Selected Presentations From the 2019 DDW Meeting • May 18-21, 2019 • San Diego, California Vedolizumab Shows Superior Efficacy Versus Adalimumab: Results […]
May 2019:
Hepatitis C
A Simplified Algorithm for the Management of Hepatitis C Infection
Douglas T. Dieterich, MD, Joseph Ahn, MD, MS, Bruce Bacon, MD, David Bernstein, MD, Marc Bourlière, MD, Steven Flamm, MD, Paul Kwo, MD, Joseph K. Lim, MD, Christian Ramers, MD, MPH, Nancy Reau, MD, Mark Sulkowski, MD, Norman Sussman, MD, and Stefan Zeuzem, MD
Proceedings From a Consensus Meeting • September 2018 Abstract: Elimination of hepatitis C virus (HCV) infection as a public health threat is a goal of […]
IBD
Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO
A Review of Selected Presentations From the 14th Congress of the European Crohn’s and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhagen, Denmark VARSITY: […]
February 2019:
Traveler’s diarrhea
A Closer Look at AEMCOLO With MMX Technology for the Treatment of Travelers’ Diarrhea
Bradley A. Connor, MD
G&H Could you please provide some background on travelers’ diarrhea? BC The clinical definition refers to diarrhea that occurs during or shortly after travel, typically from […]
December 2018:
Hepatitis C
Highlights in Hepatitis C Virus From the 2018 AASLD Liver Meeting
Highlights in Hepatitis C Virus From the 2018 AASLD Liver Meeting A Review of Selected Presentations From the 2018 AASLD Liver Meeting • November 9-13, 2018 […]
diarrhea
Emerging Options for the Management of Travelers’ Diarrhea
Robert Steffen, MD
Abstract: The incidence of travelers’ diarrhea (TD) has slightly decreased due to improvements in the hygienic conditions seen in many destination countries. However, high-risk areas […]
IBD
Highlights in IBD From the American College of Gastroenterology 2018 Annual Scientific Meeting and United European Gastroenterology Week 2018
Highlights in IBD From the American College of Gastroenterology 2018 Annual Scientific Meeting and United European Gastroenterology Week 2018 A Review of Selected Presentations From the […]
November 2018:
IBD
IBD Management: State of the Art in 2018
Raymond K. Cross, MD, MS, and Francis A. Farraye, MD, MSc
Abstract: The management of patients with inflammatory bowel disease (IBD) is evolving based on new therapies and treatment goals. Current management of IBD follows a […]
August 2018:
Colorectal Cancer
Incomplete Resection Rates in Polyps Smaller Than 2 Centimeters
David A. Johnson, MD, Michael B. Wallace, MD, MPH, Vivek Kaul, MD, FACG, FASGE, AGAF, and Tonya Kaltenbach, MD, MS
Proceedings From a Live Clinical Roundtable Held During Digestive Disease Week • June 2-5, 2018 • Washington, DC Abstract: Colorectal cancer (CRC) is the second-leading cause […]
IBD
Highlights in Ulcerative Colitis and Crohn’s Disease From the 2018 DDW Meeting
A Review of Selected Presentations From the 2018 Digestive Disease Week Meeting • June 2-5, 2018 • Washington, DC Special Reporting on: • Comparative Effectiveness of […]
May 2018:
Crohn’s disease
A Noninvasive Method to Assess Mucosal Healing in Patients With Crohn’s Disease
William J. Sandborn, MD, Maria T. Abreu, MD, and Marla C. Dubinsky, MD
Abstract: Ongoing inflammation in the gastrointestinal tract and loss of the mucosal barrier are key components of Crohn’s disease. Current treatment paradigms, including treat-to-target, are based […]
IBS
Understanding and Managing IBS and CIC in the Primary Care Setting
Brooks D. Cash, MD
Irritable bowel syndrome (IBS) and chronic idiopathic constipation (CIC) are highly prevalent chronic functional gastrointestinal (GI) disorders that are among the most common conditions seen […]
March 2018:
IBD
Improving IBD Care: A Personalized Approach to Management
Proceedings of a Symposium November 11, 2017 • Orlando, Florida A Case-Based Approach to Personalizing Care in IBD A 24-year-old man presents with new-onset bloody […]
December 2017:
Meeting Highlights
Highlights in Biosimilars From the World Congress of Gastroenterology at ACG 2017
A Review of Selected Presentations From the World Congress of Gastroenterology at ACG 2017 • October 13-18, 2017 • Orlando, Florida Highlights in Biosimilars From […]
Meeting Highlights
Highlights in Hepatitis C Virus From the 2017 AASLD Liver Meeting
A Review of Selected Presentations From the 2017 AASLD Liver Meeting • October 20-24, 2017 • Washington, DC Efficacy, Safety, and Pharmacokinetics of Glecaprevir/Pibrentasvir in […]
October 2017:
colonoscopy
New Strategies to Improve Polypectomy During Colonoscopy
Michael B. Wallace, MD, MPH
Abstract: In the United States, colorectal cancer (CRC) is the second-leading cause of cancer-related deaths. The most effective strategy for prevention of CRC is to […]
September 2017:
Meeting Highlights
Polyp Resection and Removal Procedures: Insights From the 2017 Digestive Disease Week
Carol Burke, Vivek Kaul, and Heiko Pohl
Supplement 2 Abstract: Colorectal cancer (CRC) is an important public health issue not only because of its high incidence but also for its high mortality rate. […]
February 2017:
Meeting Highlights
An Evidence-Based Approach to IBS and CIC: Applying New Advances to Daily Practice
William D. Chey, MD, AGAF, FACG, FACP
A Review of an Adjunct Clinical Symposium of the American College of Gastroenterology Meeting October 16, 2016 • Las Vegas, Nevada Abstract: Many nonpharmacologic and […]
December 2016:
Meeting Highlights
Highlights in the Treatment of Hepatitis C Virus From the 2016 AASLD Liver Meeting
Gastroenterology & Hepatology December 2016, Volume 12, Issue 12, Supplement 6 A Review of Selected Presentations From the 2016 AASLD Liver Meeting • November 11-15, 2016 […]
Hepatic encephalopathy, Primary Biliary Cholangitis
A Step-by-Step Approach to the Diagnosis and Management of Hepatic Encephalopathy in the United States, and Primary Biliary Cholangitis: Diagnosis and Management
Gastroenterology & Hepatology December 2016, Volume 12, Issue 12, Supplement 5 A Step-by-Step Approach to the Diagnosis and Management of Hepatic Encephalopathy in the United […]
October 2016:
The HCV Treatment Revolution Continues: Resistance Considerations, Pangenotypic Efficacy, and Advances in Challenging Populations
Ira M. Jacobson, MD
Gastroenterology & Hepatology October 2016, Volume 12, Issue 10, Supplement 4 Ira M. Jacobson, MD Chair, Department of Medicine Icahn School of Medicine at Mount Sinai […]
September 2016:
The Gastro & Hep Report Fall 2016
Gastroenterology & Hepatology The Gastro & Hep Report A Special Meeting Review Edition Fall 2016 Comprehensive Reports on the Latest Advances in Gastroenterology and Hepatology From: […]
August 2016:
Advances in IBS 2016: A Review of Current and Emerging Data
Gastroenterology & Hepatology August 2016, Volume 12, Issue 8, Supplement 3 Philip S. Schoenfeld, MD, MSEd, MSc Professor of Medicine Director of the GI Epidemiology Training […]
June 2016:
Meeting Highlights
Advances in the Treatment of Hepatitis C Virus Infection From the 2016 EASL Meeting
Gastroenterology & Hepatology Volume 12, Issue 6, Supplement 2 June 2016 Advances in the Treatment of Hepatitis C Virus Infection From the 2016 EASL Meeting The […]
February 2016:
Meeting Highlights
CCFA/Advances in Inflammatory Bowel Diseases 2015: Highlights in Ulcerative Colitis and Crohn’s Disease
Volume 12, Issue 2, Supplement 1 February 2016 CCFA/Advances in Inflammatory Bowel Diseases 2015: Highlights in Ulcerative Colitis and Crohn’s Disease A Review of Selected Presentations […]
November 2015:
IBD
Serologic Monitoring and Testing in IBD: Highlights From the 2015 DDW and Best Use in Clinical Practice
Volume 11, Issue 11, Supplement 4 November 2015 Serologic Monitoring and Testing in IBD: Highlights From the 2015 DDW and Best Use in Clinical Practice Digestive […]
September 2015:
The Gastro & Hep Report
Comprehensive Reports on the Latest Advances in Gastroenterology and Hepatology From: • The 50th Annual Meeting of the European Association for the Study of the Liver April […]
June 2015:
Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015
Volume 11, Issue 6, Supplement 3 June 2015 Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015 The 50th Annual Meeting of the […]
April 2015:
The Gastro & Hep Report
Gastroenterology & Hepatology Spring 2015 Comprehensive Reports on the Latest Advances in Gastroenterology & Hepatology From: American College of Gastroenterology 2014 Annual Scientific Meeting October […]
New and Emerging Treatment Options for Irritable Bowel Syndrome
Gastroenterology & Hepatology April 2015, Volume 11, Issue 4, Supplement 2 Moderator Brian E. Lacy, PhD, MD Professor of Medicine, Geisel School of Medicine at Dartmouth, Chief […]
March 2015:
IBD
Emerging Treatment Options in Mild to Moderate Ulcerative Colitis
Gastroenterology & Hepatology March 2015, Volume 11, Issue 3, Supplement 1 Moderator Gary R. Lichtenstein, MD Professor of Medicine, Director, Center for Inflammatory Bowel Disease, University of […]
December 2014:
New Diagnostic Strategies for Detection of Helicobacter pylori Infection in Pediatric Patients
Gastroenterology & Hepatology December 2014, Volume 10, Issue 12, Supplement 7 Moderator Benjamin D. Gold, MD GI Care for Kids, LLC, Children’s Center for Digestive Healthcare […]
Highlights in the Treatment of Hepatitis C Virus From the 2014 Liver Meeting
Gastroenterology & Hepatology December 2014, Volume 10, Issue 12, Supplement 6 A Review of Selected Presentations From the 2014 Liver Meeting November 7-11, 2014 • […]
October 2014:
The Gastro & Hep Report Fall 2014
Gastroenterology & Hepatology Fall 2014 A Special Meeting Review Edition Comprehensive Reports on The Latest Advances In Gastroenterology & Hepatology From: Digestive Disease Week May […]
July 2014:
Advances in Hepatic Encephalopathy From EASL 2014
Steven L. Flamm, MD
Volume 10, Issue 7, Supplement 5 Advances in Hepatic Encephalopathy From EASL 2014 A Review of Selected Presentations From the 49th Annual Meeting of the European […]
Highlights in Anti-Tumor Necrosis Factor Monitoring and Antibody Monitoring From the 2014 DDW Meeting
July 2014, Volume 10, Issue 7, Supplement 4 Highlights in Anti-Tumor Necrosis Factor Monitoring and Antibody Monitoring From the 2014 DDW Meeting Digestive Disease Week 2014 May […]
Clinical Roundtable Monograph: Clinical Rationale for Confirmation Testing After Treatment of Helicobacter pylori Infection: Implications of Rising Antibiotic Resistance
Colin W. Howden, MD, William D. Chey, MD, and Nimish B. Vakil, MD
July 2014, Volume 10, Issue 7, Supplement 3 Clinical Rationale for Confirmation Testing After Treatment of Helicobacter pylori Infection: Implications of Rising Antibiotic Resistance Moderator Colin W. […]
June 2014:
Advances in the Treatment of Hepatitis C Virus Infection From EASL 2014
Steven L. Flamm, MD
Volume 10, Issue 6, Supplement 2 The 49th Annual Meeting of the European Association for the Study of the Liver • April 9-13, 2014 • London, […]
April 2014:
The Gastro & Hep Report Spring 2014
Comprehensive Reports on the Latest Advances in Gastroenterology and Hepatology from: 2013 Advances in Inflammatory Bowel Diseases December 12-14, 2013 Hollywood, Florida 64th Annual Meeting of the […]
January 2014:
Advances in the Treatment of Hepatitis C Virus Infection from The Liver Meeting 2013
Ira M. Jacobson, MD
Volume 10, Issue 1, Supplement 1 January 2014 The 64th Annual Meeting of the American Association for the Study of Liver Diseases November 1-5, 2013 • […]
November 2013:
Clinical Roundtable Monograph: An Evidence-Based Look at Misconceptions in the Treatment of Patients with IBS-D
Brian E. Lacy, MD, PhD , William D. Chey, MD, and Lin Chang, MD
Volume 9, Issue 11, Supplement 5 November 2013 Clinical Roundtable Monograph: An Evidence-Based Look at Misconceptions in the Treatment of Patients with IBS-D Moderator Brian E. Lacy, […]
August 2013:
Clinical Research Highlights in IBD: Diagnosis and Anti-Tumor Necrosis Factor Monitoring
William J. Sandborn, MD
Volume 9, Issue 8, Supplement 4 August 2013 Clinical Research Highlights in IBD: Diagnosis and Anti-Tumor Necrosis Factor Monitoring Digestive Disease Week 2013 May 18–21, 2013 […]
June 2013:
Advances in the Treatment of Hepatitis C Virus Infection From EASL 2013
Volume 9, Issue 6, Supplement 3 June 2013 The 48th Annual Meeting of the European Association for the Study of the Liver April 24–28, 2013 • […]
April 2013:
Extending Survival With the Use of Targeted Therapy in the Treatment of Hepatocellular Carcinoma
Robert G. Gish, MD, Richard S. Finn, MD, Jorge A. Marrero, MD, MS
Moderator Robert G. Gish, MD Chief, Section of Hepatology UC San Diego Health Systems San Diego, California Discussants Richard S. Finn, MD Associate Professor of Medicine […]
The Gastro & Hep Report: Spring 2013
Comprehensive Reports on the Latest Advances in Gastroenterology and Hepatology from: • The 2012 Annual Scientific Meeting of the American College of Gastroenterology October 19–24, 2012 […]
January 2013:
Advances in the Treatment of Hepatitis C Virus Infection From AASLD 2012
Fred Poordad, MD
Volume 9, Issue 1, Supplement 1 January 2013 Advances in the Treatment of Hepatitis C Virus Infection From AASLD 2012 The 63rd Annual Meeting of the […]
November 2012:
Clinical Roundtable Monograph: Risk of Biologic Therapy–Associated Progressive Multifocal Leukoencephalopathy: Use of the JC Virus Antibody Assay in the Treatment of Moderate-to-Severe Crohn’s Disease
Gary R. Lichtenstein, MD, Stephen B. Hanauer, MD, and William J. Sandborn, MD
Abstract: For treatment of moderate-to-severe active Crohn’s disease, clinicians generally rely on immunosuppressants (including azathioprine and 6-mercaptopurine), corticosteroids, and antibodies against tumor necrosis factor α. However, a significant proportion of patients do not respond to these therapies, lose response over time, or are intolerant to these therapies. In such cases, one of the only remaining pharmacologic treatment options is natalizumab, an α4 integrin–targeted antibody. Unfortunately, 3 cases of progressive multifocal leukoencephalopathy (PML) were reported in natalizumab-treated patients in 2005, shortly after natalizumab’s approval by the US Food and Drug Administration (FDA). Natalizumab was subsequently withdrawn from the market but was then reintroduced in 2006 under close supervision by the FDA. Careful review of postmarketing data revealed 3 major risk factors for the development of natalizumab-associated PML, the most significant of which is prior exposure to the JC virus (JCV). To help identify patients who may be at higher risk for developing natalizumab-associated PML, a JCV antibody assay was developed that can detect anti-JCV antibodies in patients’ blood. Clinicians can now consider a patient’s anti-JCV antibody status together with the other major risk factors for natalizumab-associated PML—duration of natalizumab therapy and prior immunosuppressant use—to more accurately gauge the risks and benefits of natalizumab therapy in a particular patient.
Clinical Roundtable Monograph: Contemporary Diagnostic Strategies for the Detection of Helicobacter pylori Infection
Adam B. Elfant, MD, FACG, Colin W. Howden, MD, and Neil Stollman, MD, FACP, FACG, AGAF
Helicobacter pylori infection is highly prevalent, affecting approximately half of the world’s population. While the majority of infected individuals are asymptomatic, H. pylori infection is associated with certain diseases, including peptic ulcers (either duodenal or gastric), gastritis, and 2 malignancies—gastric cancer and gastric mucosa–associated lymphoid tissue lymphoma. Many of the epidemiologic associations between these diseases and H. pylori infection have been further validated by treatment studies, which show that effective eradication therapy correlates with a decreased risk of disease. A variety of testing strategies are used to detect H. pylori infection. Serologic techniques are widely available and inexpensive, but they are no longer preferred as they have low sensitivities and specificities, and they may show a positive result for a long period following effective therapy. The remaining testing methods are divided into 2 categories: invasive tests (which require endoscopy) and noninvasive tests. Noninvasive test methods such as the urea breath test and stool antigen test have gained popularity due to their high sensitivities and specificities. Further, both of these methods may be used to confirm the absence of infection following eradication therapy. Due to the increasing incidence of treatment failure (caused in part by antibiotic resistance), post-treatment testing is recommended to confirm H. pylori eradication.
October 2012:
The Gastro & Hep Report: Fall 2012
Comprehensive Reports on the Latest Advances in Gastroenterology and Hepatology From:
• The 47th Annual Meeting of the European Association for the Study of the Liver
April 18–22, 2012 • Barcelona, Spain
• Digestive Disease Week 2012
May 19–22, 2012 • San Diego, California
September 2012:
Clinical Roundtable Monograph: Anemia Management in the Era of Triple Combination Therapy for Chronic HCV
Ira M. Jacobson, MD, Kris V. Kowdley, MD, FACP, FACG, AGAF, and Paul Y. Kwo, MD
Boceprevir or telaprevir plus ribavirin (RBV) and pegylated interferon-α (pegIFN-α) is the new standard-of-care therapy for patients who are chronically infected with genotype 1 hepatitis C virus (HCV). The addition of these protease inhibitors to the RBV/pegIFN-α combination regimen has significantly improved rates of sustained virologic response (SVR); however, the incidence of anemia has also increased significantly. Anemia can interfere with patients’ quality of life, work productivity, and treatment adherence. Severe anemia can cause morbidity and even mortality. For the management of anemia during triple combination therapy, RBV dose reduction is recommended as an initial course of action. Retrospective analyses of carefully selected patient cohorts suggest that RBV dose reduction does not reduce SVR rates. However, this observation needs to be confirmed in prospective trials with cohorts that more accurately reflect the challenging patients treated in real-world practice. Adequate doses of RBV should be maintained during triple combination therapy, as phase II trials have demonstrated that RBV is essential for attaining optimal SVR rates and preventing viral breakthrough, relapse, and emergence of resistant variants. This roundtable addresses key points related to the management of anemia in the era of triple combination therapy, including the increasing problem of anemia, strategies for anemia management, and the importance of maintaining adequate RBV exposure as part of the HCV treatment regimen.
August 2012:
Highlights in Crohn’s Disease and Ulcerative Colitis
William J. Sandborn, MD
Special Reporting on:
• Safety and Efficacy of Subcutaneous Golimumab Induction Therapy in Patients with Moderately to Severely Active UC: PURSUIT-SC
• The Future of IBD Therapy: Individualized and Optimized Therapy and Novel Mechanisms
• Infliximab Concentration and Clinical Outcome in Patients with UC
• Vedolizumab Induction Therapy for UC: Results of GEMINI I, A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase III Trial
• Novel Infliximab and Antibody-to-Infliximab Assays Are Predictive of Disease Activity in Patients with CD
• Accelerated Step-Care Therapy with Early Azathioprine Versus Conventional Step-Care Therapy in CD
• PIANO: A 1,000-Patient Prospective Registry of Pregnancy Outcomes in Women with IBD Exposed to Immunomodulators and Biologic Therapy
July 2012:
Highlights in Anti–Tumor Necrosis Factor Monitoring
William J. Sandborn, MD
Special Reporting on:
• Novel Infliximab and Antibody-to-Infliximab Assays Are Predictive of Disease Activity in Patients with Crohn’s Disease
• Antibodies to Infliximab Can Either Be Persistent or Transient: A Retrospective Case-Control Study in IBD Patients Treated with Infliximab Maintenance Therapy
• Putting It Together: Drug Levels and Disease Activity to Tailor Therapy
• Infliximab Concentration and Clinical Outcome in Patients with Ulcerative Colitis
June 2012:
Case Study Monograph: Community Perspectives: Combining Serology,
Genetics, and Inflammation Markers for the Diagnosis
of IBD and Differentiation Between CD and UC
Douglas C. Wolf, MD, Bincy P. Abraham, MD, MS, Anita Afzali, MD, MPH, Paul D. Allegretti, DO, and Ronen Arai, MD
Diagnosis of inflammatory bowel disease (IBD) is complicated and is based on a combination of patient history and physical examination in association with laboratory, endoscopic, histologic, and radiographic investigations. Determination of the correct diagnosis is important for its implications in selecting treatment and in the timing and type of surgery that may be required. Information from testing incorporating serologic, genetic, and inflammatory markers can help to clarify the clinical picture. Measurement of biomarkers not only helps to differentiate a diagnosis of IBD versus non-IBD, it can also help to distinguish between ulcerative colitis and Crohn’s disease in difficult cases. In this monograph, 5 cases illustrate how specialized testing can provide important information that can aid in diagnosis.
Updates in the Treatment of Hepatitis C Virus Infection From EASL 2012
Jean-Pierre Bronowicki, MD, PhD
Special Reporting on:
• Safety of Telaprevir or Boceprevir in Combination with Peginterferon α/
Ribavirin in Cirrhotic Nonresponders. First Results of the French Early Access Program (ANRS CO20-CUPIC)
• SVR in Prior Peginterferon/Ribavirin (PR) Treatment Failures After
Re-treatment with Boceprevir + PR: The PROVIDE Study Interim Results
• Futility Rules in Telaprevir Combination Treatment
• Boceprevir Plus Peginterferon/Ribavirin for the Treatment of HCV/HIV Co-Infected Patients: End-of-Treatment (Week 48) Interim Results
PLUS Meeting Abstract Summaries
March 2012:
The Gastro & Hep Report: Spring 2012
Comprehensive Reports on the Latest Advances in Gastroenterology and Hepatology From:
• The 76th American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course
October 28–November 2, 2011
Washington, DC
• The 62nd Annual Meeting of the American Association for the Study of Liver Diseases
November 4–8, 2011
San Francisco, California
• 2011 Advances in Inflammatory Bowel Diseases/Crohn’s & Colitis Foundation’s Clinical and Research Conference
December 1–3, 2011
Hollywood, Florida
January 2012:
Highlights in the Treatment of Hepatitis C Virus Infection From AASLD 2011
John M. Vierling, MD, FACP
Gastroenterology & Hepatology Volume 8, Issue 1, Supplement 1 January 2012 A SPECIAL MEETING REVIEW EDITION Highlights in the Treatment of Hepatitis C Virus Infection […]
October 2011:
August 2011:
July 2011:
Clinical Roundtable Monograph: New Developments in the Treatment of Hepatitis C Virus (HCV): A Roadmap for the Diagnosis, Treatment, and Management of Patients with HCV
Fred Poordad, MD, Bruce R. Bacon, MD, Mark S. Sulkowski, MD
Volume 7, issue 7, Supplement 12 July 2011
Clinical Roundtable Monograph: Recent Advances in Optimal Bowel Preparation
Philip S. Schoenfeld, MD, MSEd, MSc (Epi), Carol A. Burke, MD, Lawrence B. Cohen, MD, David M. Kastenberg , MD
Volume 7, Issue 7, Supplement 11 July 2011
June 2011:
New Developments in the Treatment of Hepatitis C Virus Infection from Digestive Disease Week 2011
Steven L. Flamm, MD
Volume 7, Issue 6, Supplement 10 June 2011 New Developments in the Treatment of Hepatitis C Virus Infection from Digestive Disease Week 2011 May 7–10, 2011 […]
May 2011:
Clinical Roundtable Monograph: Community Perspectives on Serologic and Genetic Testing for Crohn’s Disease
Marla C. Dubinsky, MD, Morris A. Barocas, MD, Charles J. Loewe, MD, Chandar Singaram, MD, MBA, Ronald Soltis, MD, Jeffrey A. Tuvlin, MD
Volume 7, issue 5, Supplement 8 May 2011
Clinical Roundtable Monograph: Optimizing Patient Outcomes in the Treatment of Ulcerative Colitis
Patrick G. Brady, MD, Gary R. Lichtenstein, MD, Paul J. Rutgeerts, MD, PhD, FRCP, AGAF
Volume 7, issue 5, Supplement 7 May 2011
April 2011:
Clinical Roundtable Monograph: Clinical Perspectives on Infliximab for the Treatment of Crohn’s Disease: Considerations from the SONIC Study
Gary R. Lichtenstein, MD, Asher Kornbluth, MD, Geert D’Haens, MD, PhD
Volume 7, Issue 4, Supplement 6 april 2011
Clinical Roundtable Monograph: Safety of Proton Pump Inhibitors
David A. Johnson, MD, David A. Peura, MD, Michael F. Vaezi, MD
Volume 7, Issue 4, Supplement 5 april 2011
March 2011:
Clinical Roundtable Monograph: Chronic Hepatitis B: Integrating Long-Term Treatment Data and Strategies to Improve Outcomes in Clinical Practice
Nezam H. Afdhal, MD, Bruce R. Bacon, MD, Robert S. Brown, Jr., MD, MPH
Volume 7, Issue 3, Supplement 4 March 2011
February 2011:
Progress in the Diagnosis and Treatment of Inflammatory Bowel Disease
Edward V. Loftus, Jr., MD
Volume 7, Issue 2, Supplement 3 February 2011